Alvine Pharmaceuticals is dedicated to developing and commercializing therapeutics for the treatment of celiac sprue, a gluten-induced autoimmune disease for which no drug therapy is currently available. Celiac sprue is believed to affect as many as two million people in the U.S. alone, many of whom have suffered the symptoms of the disease but have not yet been diagnosed.
Investors 2
Funding Rounds 2
| Date | Series | Amount | Investors |
| 24.06.2008 | - | $26M | - |
| 06.09.2006 | - | $8M | Sofinnova ... |
Mentions in press and media 6
| Date | Title | Description |
| 24.01.2013 | Biopharma testing celiac disease drug to break down gluten | Celiac disease is characterized by an immune response elicited by the ingestion of gluten, a storage protein found in wheat, rye and barley. That response affects the process of the small intestine and can inhibit the absorption of nutrient... |
| 26.05.2010 | Alvine Pharmaceuticals Raises Additional Funds from Abbott Biotech Ventures | Alvine Pharmaceuticals, Inc., a San Carlos, CA-based clinical stage biopharmaceutical company focused on developing and commercializing therapeutics for autoimmune and inflammatory diseases, has recieved an undisclosed equity investment fro... |
| 15.09.2009 | USA, Alvine Pharmaceuticals Raises $21.5M Series A Extension Funding | Alvine Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing therapeutics for autoimmune/gastrointestinal diseases, closed a $21.5m extension of its Series A financing.
New investor Panorama Capital led the ... |
| 24.06.2008 | Alvine Pharmaceuticals raises $26 million for disease research | San Carlos, Calif. company Alvine Pharmaceuticals recently added $5 million to its first venture round, bringing total funding to $26 million, according to VentureWire.
Alvine’s research focuses on treatment for autoimmune and gastrointesti... |
| 06.09.2006 | Alvine Pharma raises nearly $8M from Prospect, Sofinnova | Alvine Pharmaceuticals Inc., a Palo Alto, Calif.-based drug company focused on Celiac disease, has secured nearly $8 million of a $21.33 million Series A round, according to a regulatory filing. Backers include Prospect Venture Partners and... |
| - | Biopharma testing celiac disease drug to break down gluten | A biopharmaceutical company that’s already raised at least $42 million for its celiac disease drug now has $6 million more as it works through a second phase 2 trial.
Alvine Pharmaceuticals’ lead candidate is a mix of two recombinant gluten... |
Reviews 0
